Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans
Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans
复制标题
DOI:
10.1038/npp.2015.53
复制
发表时间:
2015-08-01
影响因子:
7.6
通讯作者:
D'Souza, Deepak Cyril
中科院分区:
文献类型:
--
作者:
Cortes-Briones, Jose;Skosnik, Patrick D.;D'Souza, Deepak Cyril
Gamma (gamma)-band oscillations play a key role in perception, associative learning, and conscious awareness and have been shown to be disrupted by cannabinoids in animal studies. The goal of this study was to determine whether cannabinoids disrupt gamma-oscillations in humans and whether these effects relate to their psychosis-relevant behavioral effects. The acute, dose-related effects of Delta-9-tetrahydrocannabinol (Delta(9)-THC) on the auditory steady-state response (ASSR) were studied in humans (n=20) who completed 3 test days during which they received intravenous Delta(9)-THC (placebo, 0.015, and 0.03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design. Electroencephalography (EEG) was recorded while subjects listened to auditory click trains presented at 20, 30, and 40 Hz. Psychosis-relevant effects were measured with the Positive and Negative Syndrome scale (PANSS). Delta(9)-THC (0.03 mg/kg) reduced intertrialcoherence (ITC) in the 40 Hz condition compared with 0.015 mg/kg and placebo. No significant effects were detected for 30 and 20 Hz stimulation. Furthermore, there was a negative correlation between 40 Hz ITC and PANSS subscales and total scores under the influence of Delta(9)-THC. Delta(9)-THC (0.03 mg/kg) reduced evoked power during 40 Hz stimulation at a trend level. Recent users of cannabis showed blunted Delta(9)-THC effects on ITC and evoked power. We show for the first time in humans that cannabinoids disrupt gamma-band neural oscillations. Furthermore, there is a relationship between disruption of gamma-band neural oscillations and psychosis-relevant phenomena induced by cannabinoids. These findings add to a growing literature suggesting some overlap between the acute effects of cannabinoids and the behavioral and psychophysiological alterations observed in psychotic disorders.